Pancreatic cystadenocarcinoma

Summary

Pancreatic cystadenocarcinoma (MONDO:0002867) is a disease and 1 clinical trial. A subtype of cystadenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pancreatic cystadenocarcinoma
Mondo ID	MONDO:0002867
DOID	DOID:4073
NCIT	C3874
SNOMED CT	235966007
UMLS	C0238337
MedGen	66767
GARD	0027622
Anatomy (UBERON)	UBERON:0001264
Is cancer (heuristic)	no

Also known as: cystadenocarcinoma - pancreas · cystadenocarcinoma of pancreas · cystadenocarcinoma of the pancreas · pancreas cystadenocarcinoma · pancreatic cystadenocarcinoma

Disease family

An umbrella term covering 3 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › cystadenocarcinoma › pancreatic cystadenocarcinoma

Related subtypes (5): ovarian cystadenocarcinoma, papillary cystadenocarcinoma, mucinous cystadenocarcinoma, biliary cystadenocarcinoma, serous cystadenocarcinoma

Subtypes (3): pancreatic serous cystadenocarcinoma, pancreatic mucinous cystadenocarcinoma, pancreatic acinar cell cystadenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03884179	Not specified	UNKNOWN	Diagnosis of PCL With EUS-FNA and Cross-sectional Imaging - A Report of Accuracy